Molecular biomarkers for future screening of lung cancer

Journal of Surgical Oncology

Volumn 108, Issue 5, 2013, Pages 327-333

  Hensing, Thomas A ^a   Salgia, Ravi ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

biomarkers; early diagnosis; lung cancer; review; screening

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; SQUAMOUS CELL CARCINOMA ANTIGEN;

BLOOD ANALYSIS; BREATH ANALYSIS; CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; LOW DOSE COMPUTER ASSISTED TOMOGRAPHY; LUNG CANCER; LUNG NODULE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIODIAGNOSIS; RESPIRATORY EPITHELIUM; RETROSPECTIVE STUDY; REVIEW; SCREENING; SMOKING; SPUTUM; VALIDATION PROCESS;

BIOMARKERS; EARLY DIAGNOSIS; LUNG CANCER; REVIEW; SCREENING;

BREATH TESTS; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84884903673     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23382     Document Type: Review

References (92)

1. Siegel R, Naishadham D, Jemal A:, Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Spiro SG, Silvestri GA:, One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172: 523-529.
3. Aberle DR, Adams AM, Berg CD, et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
4. Wood DE, Eapen GA, Ettinger DS, et al.: Lung cancer screening. J Natl Compr Cancer Netw 2012; 10: 240-265.
5. Arenberg D, Kazerooni EA:, Setting up a lung cancer screening program. J Natl Compr Cancer Netw 2012; 10: 277-285.
6. Bach PB, Mirkin JN, Oliver TK, et al.: Benefits and harms of CT screening for lung cancer: A systematic review. JAMA 2012; 307: 2418-2429.
7. Tammemagi MC, Katki HA, Hocking WG, et al.: Selection criteria for lung-cancer screening. N Engl J Med 2013; 368: 728-736.
8. Hassanein M, Callison JC, Callaway-Lane C, et al.: The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila) 2012; 5: 992-1006.
9. Pepe MS, Feng Z, Janes H, et al.: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 2008; 100: 1432-1438.
10. Pepe MS, Etzioni R, Feng Z, et al.: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-1061.
11. Roy HK, Hensing T, Backman V:, Nanocytology for field carcinogenesis detection: Novel paradigm for lung cancer risk stratification. Future Oncol 2011; 7: 1-3.
12. Liloglou T, Bediaga NG, Brown BR, et al.: Epigenetic biomarkers in lung cancer. Cancer Lett 2012, http://dx.doi.org/10.1016/j.canlet.2012.04.018.
13. Horvath I, Lazar Z, Gyulai N, et al.: Exhaled biomarkers in lung cancer. Eur Respir J 2009; 34: 261-275.
14. Rahman SMJ, Gonzalez AL, Li M, et al.: Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res 2011; 71: 3009-3017.
15. Schmidt B, Liebenberg V, Dietrich D, et al.: SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010; 10: 600.
16. Kneip C, Schmidt B, Seegebarth A, et al.: SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011; 6: 1632-1638, doi: 10.1097/JTO.0b013e318220ef9a
17. Spira A, Beane JE, Shah V, et al.: Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007; 13: 361-366.
18. Massion PP, Zou Y, Uner H, et al.: Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer. PLoS ONE 2009; 4: e5611.
19. Beane J, Sebastiani P, Whitfield TH, et al.: A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res 2008; 1: 56-64.
20. Roy HK, Subramanian H, Damania D, et al.: Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: Implications for screening. Cancer Res 2010; 70: 7748-7754.
21. Sidransky D:, The oral cavity as a molecular mirror of lung carcinogenesis. Cancer Prev Res (Phila) 2008; 1: 12-14.
22. Bhutani M, Pathak AK, Fan YH, et al.: Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) 2008; 1: 39-44.
23. Subramanian H, Roy HK, Pradhan P, et al.: Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res 2009; 69: 5357-5363.
24. Melamed MR:, Lung cancer screening results in the National Cancer Institute New York study. Cancer 2000; 89: 2356-2362.
25. Thunnissen FB:, Sputum examination for early detection of lung cancer. J Clin Pathol 2003; 56: 805-810.
26. Palmisano WA, Divine KK, Saccomanno G, et al.: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-5958.
27. Belinsky SA, Palmisano WA, Gilliland FD, et al.: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002; 62: 2370-2377.
28. Belinsky SA, Grimes MJ, Casas E, et al.: Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007; 96: 1278-1283.
29. Xing L, Todd NW, Yu L, et al.: Early detection of squamous cell.: Lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010; 23: 1157-1164.
30. Yu L, Todd NW, Xing L, et al.: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010; 127: 2870-2878.
31. Hwang SH, Kim KU, Kim JE, et al.: Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clin Chem Lab Med 2011; 49: 699-704.
32. Li R, Todd NW, Qiu Q, et al.: Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res 2007; 13: 482-487.
33. Belinsky SA:, Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 707-717.
34. Mazzone PJ:, Beyond the usual suspects. J Thorac Oncol 2012; 7: 1477-1478.
35. Esther CR, Jr., Jasin HM, Collins LB, et al.: A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate. Rapid Commun Mass Spectrom 2008; 22: 701-705.
36. Bayley DL, Abusriwil H, Ahmad A, et al.: Validation of assays for inflammatory mediators in exhaled breath condensate. Eur Respir J 2008; 31: 943-948.
37. Gessner C, Rechner B, Hammerschmidt S, et al.: Angiogenic markers in breath condensate identify non-small cell lung cancer. Lung Cancer 2010; 68: 177-184.
38. Kurova VS, Kononikhin AS, Sakharov DA, et al.: Exogenic proteins in the human exhaled breath condensate. Bioorg Khim 2011; 37: 55-60.
39. Chen X, Xu F, Wang Y, et al.: A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer 2007; 110: 835-844.
40. Phillips M, Gleeson K, Hughes JMB, et al.: Volatile organic compounds in breath as markers of lung cancer: A cross-sectional study. Lancet 1999; 353: 1930-1933.
41. Phillips M, Cataneo RN, Cummin AR, et al.: Detection of lung cancer with volatile markers in the breath. Chest 2003; 123: 2115-2123.
42. Phillips M, Altorki N, Austin JH, et al.: Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta 2008; 393: 76-84.
43. Poli D, Carbognani P, Corradi M, et al.: Exhaled volatile organic compounds in patients with non-small cell lung cancer: Cross sectional and nested short-term follow-up study. Respir Res 2005; 6: 71.
44. Bajtarevic A, Ager C, Pienz M, et al.: Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009; 9: 348.
45. Peled N, Hakim M, Bunn PA, Jr., et al.: Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol 2012; 7: 1528-1533.
46. Phillips M, Altorki N, Austin JH, et al.: Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark 2007; 3: 95-109.
47. Mazzone PJ:, Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. J Thorac Oncol 2008; 3: 774-780.
48. Machado RF, Laskowski D, Deffenderfer O, et al.: Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 2005; 171: 1286-1291.
49. Dragonieri S, Annema JT, Schot R, et al.: An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009; 64: 166-170.
50. McCulloch M, Jezierski T, Broffman M, et al.: Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr Cancer Ther 2006; 5: 30-39.
51. Ehmann R, Boedeker E, Friedrich U, et al.: Canine scent detection in the diagnosis of lung cancer: Revisiting a puzzling phenomenon. Eur Respir J 2012; 39: 669-676.
52. Boedeker E, Friedel G, Walles T:, Sniffer dogs as part of a bimodal bionic research approach to develop a lung cancer screening. Interact Cardiovasc Thorac Surg 2012; 14: 511-515.
53. Hassanein M, Rahman JS, Chaurand P, et al.: Advances in proteomic strategies toward the early detection of lung cancer. Proc Am Thorac Soc 2011; 8: 183-188.
54. Showe MK, Vachani A, Kossenkov AV, et al.: Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009; 69: 9202-9210.
55. Tanaka F, Yoneda K, Kondo N, et al.: Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009; 15: 6980-6986.
56. Krebs MG, Hou JM, Sloane R, et al.: Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 2012; 7: 306-315.
57. Hou JM, Krebs MG, Lancashire L, et al.: Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30: 525-532.
58. Bremnes RM, Sirera R, Camps C:, Circulating tumour-derived DNA and RNA markers in blood: A tool for early detection, diagnostics, and follow-up ? Lung Cancer 2005; 49: 1-12.
59. Greenberg AK, Rimal B, Felner K, et al.: S-Adenosylmethionine as a biomarker for the early detection of lung cancer. CHEST J 2007; 132: 1247-1252.
60. Begum S, Brait M, Dasgupta S, et al.: An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 2011; 17: 4494-4503.
61. Anglim PP, Galler JS, Koss MN, et al.: Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 2008; 7: 62.
62. Tsou JA, Galler JS, Siegmund KD, et al.: Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 2007; 6: 70.
63. Richards KL, Zhang B, Sun M, et al.: Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer 2011; 117: 606-617.
64. Dietrich D, Kneip C, Raji O, et al.: Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 2012; 40: 825-832.
65. Zhang Y, Wang R, Song H, et al.: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011; 303: 21-28.
66. Wei J, Gao W, Zhu CJ, et al.: Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011; 30: 407-414.
67. Boeri M, Verri C, Conte D, et al.: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci 2011; 108: 3713-3718.
68. Shen J, Todd NW, Zhang H, et al.: Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011; 91: 579-587.
69. Chen X, Ba Y, Ma L, et al.: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
70. Chen X, Hu Z, Wang W, et al.: Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012; 130: 1620-1628.
71. Bianchi F, Nicassio F, Marzi M, et al.: A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011; 3: 495-503.
72. Hennessey PT, Sanford T, Choudhary A, et al.: Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 2012; 7: e32307.
73. Lee HJ, Kim YT, Park PJ, et al.: A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling. J Thorac Cardiovasc Surg 2012; 143: 421-427.
74. Yildiz PB, Shyr Y, Rahman JS, et al.: Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007; 2: 893-901.
75. Pecot CV, Li M, Zhang XJ, et al.: Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev 2012; 21: 786-792.
76. Patz EF, Jr., Caporaso NE, Dubinett SM, et al.: National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): Design, intent, and availability of specimens for validation of lung cancer biomarkers. J Thorac Oncol 2010; 5: 1502-1506.
77. Leidinger P, Keller A, Ludwig N, et al.: Toward an early diagnosis of lung cancer: An autoantibody signature for squamous cell lung carcinoma. Int J Cancer 2008; 123: 1631-1636.
78. Farlow EC, Patel K, Basu S, et al.: Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010; 16: 3452-3462.
79. Mazzone PJ, Hammel J, Dweik R, et al.: Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax 2007; 62: 565-568.
80. Kulpa J, Wõjcik E, Reinfuss M, et al.: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48: 1931-1937.
81. Patz EF, Campa MJ, Gottlin EB, et al.: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007; 25: 5578-5583.
82. Takano A, Ishikawa N, Nishino R, et al.: Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009; 69: 6694-6703.
83. Diamandis EP, Goodglick L, Planque C, et al.: Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 2011; 17: 2395-2399.
84. Taguchi A, Politi K, Pitteri SJ, et al.: Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011; 20: 289-299.
85. Zhong L, Coe SP, Stromberg AJ, et al.: Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006; 1: 513-519.
86. Pereira-Faca SR, Kuick R, Puravs E, et al.: Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res 2007; 67: 12000-12006.
87. Chapman CJ, Murray A, McElveen JE, et al.: Autoantibodies in lung cancer: Possibilities for early detection and subsequent cure. Thorax 2008; 63: 228-233.
88. Qiu J, Choi G, Li L, et al.: Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008; 26: 5060-5066.
89. Rom WN, Goldberg JD, Addrizzo-Harris D, et al.: Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer 2010; 10: 234.
90. Leidinger P, Keller A, Heisel S, et al.: Identification of lung cancer with high sensitivity and specificity by blood testing. Respir Res 2010; 11: 18.
91. Wu L, Chang W, Zhao J, et al.: Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res 2010; 16: 3760-3768.
92. Boyle P, Chapman CJ, Holdenrieder S, et al.: Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011; 22: 383-389.